Page 3 - Nasdaq Bcli News Today

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.20 and traded as high as $3.16. Brainstorm Cell Therapeutics shares last traded at $2.78, with a volume of 440,422 shares trading […]

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 3,100,000 shares, a growth of 29.7% from the March 15th total of 2,390,000 shares. Currently, 11.0% of the company’s stock are sold short. Based on an […]

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04, Yahoo Finance reports. During the same quarter in the prior year, the company earned ($0.17) EPS. Brainstorm Cell Therapeutics Stock Performance BCLI traded up […]

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) released its earnings results on Thursday. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04, Yahoo Finance reports. During the same period in the prior year, the firm posted ($0.17) earnings per share. Brainstorm Cell Therapeutics Trading Up 32.0 % […]

StockNews.com cut shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) from a hold rating to a sell rating in a research note released on Sunday morning. Brainstorm Cell Therapeutics Price Performance BCLI opened at $2.44 on Friday. Brainstorm Cell Therapeutics has a fifty-two week low of $1.09 and a fifty-two week high of $4.70. […]

StockNews.com lowered shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Sunday morning. Brainstorm Cell Therapeutics Stock Performance Shares of NASDAQ BCLI opened at $1.84 on Friday. The firm has a market cap of $67.23 million, a price-to-earnings ratio […]

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock. Shares of BCLI stock opened at $3.02 on Tuesday. The stock has a market cap of $110.19 million, a P/E […]

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) and Molecular Partners (NASDAQ:MOLN – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk. Insider & Institutional Ownership 12.3% of Brainstorm Cell […]

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends. Profitability This table compares Brainstorm Cell Therapeutics and […]

Equities analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) to announce earnings of ($0.13) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics posted earnings of ($0.19) per share during the same quarter last year, which would […]